Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

In the last 5 years, FDA has actively characterized innovative ECG analysis methods for proarrhythmia assessments in clinical trials. ECG is a cornerstone of cardiac safety monitoring in toxicology and safety pharmacology with similarities between clinical and non-clinical evaluations.

A presentation was given by CitoxLab North America during SOT Annual Meeting & ToxExpo 2019, in Baltimore:

Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

 

Other posts you may like

Software solution with SEND compatible outputs

Discover how emka helps you to comply with regulatory guidance

Transonic Microsurgery Workshop

October 21-23, 2019 René Remie Surgical Skills Centre Almere, The Netherlands

American Thoracic Society

May 17-22, 2019 Dallas,  Texas – USA Booth #3619

EB 2019

April 6-9, 2019 Orlando, Florida - USA Booth #916